Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT ...

Drug pricing has been under increased scrutiny under both the Trump and Biden administrations, including changes to cap ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration (“HRSA”), an administrative agency under ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...